LennardMSTuckerGTWoodsHF. Inborn “errors” of drug metabolism; pharmacokinetics and clinical implications. Clin Pharmacokinet1990; 19: 257–63.
2.
EvansWERellingMVPetrosWP, Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquine oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther1989; 45: 568–73.
3.
RamsayLESilasJHOllerenshawJD, Should the acetylator phenotype be determined when prescribing hydralazine for hypertension. Eur J Clin Pharmacol1984; 26: 39–42.
4.
RahavGZylber-KatzERachmilewitzD., Relationship between the acetylator phenotype, plasma sulfapyridine levels and advese effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. Isr J Med Sci1990; 26: 31–4.
5.
GrantDMMorikeKEichelbaumM., Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest1990; 85: 968–72.
6.
RiederMJShearNHKaneeA., Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol1991; 49: 13–7.
7.
RiederMJUetrechtJShearNH, Diagnosis of sulfonamide hypersensitivity reactions by in vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med1989; 110: 286–9.
8.
WeinshilboumR.Pharmacogenetics of methylation: Relationship to drug metabolism. Clin Biochem1988; 21: 201–10.
9.
LennardLVan LoonJALilleymanJS, Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther1987; 41: 18–25.
10.
LennardLLilleymanJS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol1989; 7: 1816–23.
11.
LennardLVan LoonJAWeinshilboumRM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther1989; 46: 149–54.
WaringRHSteventonGBSturmanSG, 5-Methylation in motomeuron disease and Parkinson's disease. Lancet1989; 2: 356–7.
14.
ReillyDKRivera-CalimlimLVan DykeD.Catechol O-methyltransferase activity: A determinant of levodopa response. Clin Pharmacol Ther1980; 28: 278–86.
15.
CampbellNRCDunnetteJHMwalukoG., Platelet phenol sulfotransferase and erythrocyte catechol O-methyltransferase activities: Correlation with methyldopa metabolism in man. Clin Pharmacol Ther1984; 35: 55–63.
16.
BrosenK.Recent developments in hepatic drug oxidation; implications for clinical pharmacokinetics. Clin Pharmacokinet1990; 18: 220–39.
17.
GuengerichFP. Characterization of human microsomal cytochrome P450 enzymes. Ann Rev Pharmacol Toxicol1989; 29: 241–64.
18.
GonzalezFJ. Molecular genetics of the P450 superfamily. Pharmacol Ther1990; 45: 1–38.
19.
HouZ-YPickleLWMeyerPS, Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther1991; 49: 410–9.
20.
LennardMS. Genetic polymorphism of sparteine/debrisoquine oxidation: A reappraisal. Pharmacol Toxicol1990; 67: 273–83.
21.
JacksonPRTuckerGT. Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphism in xenobiotic metabolism. Ann Occup Hyg1990; 34: 653–62.
22.
AyeshRDawlingSHaylerA., Comparative effects of the di-astereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality1991; 3: 14–8.
23.
HeimMMeyerUA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet1990; 336: 529–32.
24.
DayerPDesmeulesJLeemannT., Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun1988; 152: 411–6.
DesmeulesHWDayerPGasconM-P, Impact of genetic and environmental factors on codeine analgesia (abstract). Clin Pharmacol Ther1989; 45: 122.
27.
MikusGGrossASBeckmannR., The influence of the sparteine/debrisoquine phenotype on the disposition of flecainide. Clin Pharmacol Ther1989; 45: 562–7.
28.
GrossASMikusGFischerC., Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. Eur J Clin Pharmacol1991; 40: 155–62.
29.
LennardMS. The polymorphic oxidation of beta-adrenoceptor antagonists. Pharmacol Ther1989; 41: 461–77.
30.
JonkersREKoopmansRPPortierEJG, Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther1991; 256: 959–66.
31.
BrosenKZeuginTMeyerUA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of Imipramine. Clin Pharmacol Ther1991; 49: 609–17.
32.
Dahl-PuustinenMLJohanssonIIngelman-SundbergM., Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther1989; 46: 78–81.
33.
TyndaleRFKalowWInabaT.Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol1991; 31: 655–60.
34.
von BahrCMovinGNordinC., Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther1991; 49: 234–40.
